An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.
Public ClinicalTrials.gov record NCT05562934. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Resistant Hypertension
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this 20-week randomized double-blind study in patients with resistant hypertension (rHTN) is to evaluate the efficacy, safety, and tolerability, of different doses of XXB750 administered as subcutaneous (SC) injections, compared to placebo. Since all study participants will be patients with rHTN, all study treatments will be given on top of maximally tolerated background antihypertensive therapy recommended by international guidelines for treatment of HTN (i.e., a thiazide or a thiazide-like diuretic, an angiotensin converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB), and a long-acting dihydropyridine calcium channel blocker (CCB).
Study identification
- NCT ID
- NCT05562934
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 189 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 7, 2022
- Primary completion
- Jul 1, 2024
- Completion
- Aug 26, 2024
- Last update posted
- Jan 11, 2026
2022 – 2024
United States locations
- U.S. sites
- 18
- U.S. states
- 10
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pinnacle Research Group Llc | Anniston | Alabama | 36207 | — |
| Parkway Medical Center | Birmingham | Alabama | 35206 | — |
| Clinical Trials Research Sacramento | Sacramento | California | 95821-2134 | — |
| Orange County Research Center | Tustin | California | 92780 | — |
| Jacksonville Center for Clinical Research | Jacksonville | Florida | 32216 | — |
| Canvas Clinical Research | Lake Worth | Florida | 33467 | — |
| Inpatient Research Clinical LLC | Miami Lakes | Florida | 33014 | — |
| Cardiology Partners Clinical Research Institute | Wellington | Florida | 33449 | — |
| American Clinical Trials | Acworth | Georgia | 30101 | — |
| Alliance for Multispecialty Resrch | Wichita | Kansas | 67207 | — |
| Anderson Medical Research | Ft. Washington | Maryland | 20744 | — |
| Capitol Cardiology Associates | Lanham | Maryland | 20706 | — |
| MD Medical Research | Oxon Hill | Maryland | 20745 | — |
| NexGen Research | Lima | Ohio | 45801 | — |
| The Research Center of the Upstate | Greenville | South Carolina | 29607 | — |
| Tennessee Center For Clinical Trials | Tullahoma | Tennessee | 37388 | — |
| Manassas Clinical Research Center | Manassas | Virginia | 20110 | — |
| Dominion Medical Associates | Richmond | Virginia | 23219 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 60 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05562934, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 11, 2026 · Synced Sep 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05562934 live on ClinicalTrials.gov.